Revalesio
Tacoma, US · Delaware corporation
Revalesio is a clinical-stage pharmaceutical company developing therapies that target mitochondrial function to address the bioenergetic and metabolic failures underlying stroke, neurodegenerative diseases, and aging. It focuses on protecting mitochondrial structure and restoring cellular homeostasis for patients with neurological conditions lacking effective treatment options.
Founders & leadership
GA
GREG ARCHAMBEAUExecutive
BB
BRUCE BUSKIRKExecutive
ER
Eric RussellNamed on SEC filing
LH
Lee HuntsmanNamed on SEC filing
MR
Marsha RussellNamed on SEC filing
SW
Scott WalcheckNamed on SEC filing
PC
Patrick CaruanaNamed on SEC filing
KB
Karl BandlienNamed on SEC filing
Board
JN
JAMES NORDSTROMBoard director
ER
ERIC RUSSELLBoard director
CF
CHRIS FIBIGERBoard director
BV
BERT VAN DEN BERGHBoard director
Reported raises · per SEC filings
Form D private placements$92.7M disclosed across 5 rounds · 2014–2022
▶$38.9MraisedDec 2025 · 31 investors · PharmaceuticalsRule 506(b)
▶$38.9MraisedDec 2025 · 31 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- JAMES NORDSTROMDirector
- ERIC RUSSELLDirector
- GREG ARCHAMBEAUExecutive Officer
- CHRIS FIBIGERDirector
- BERT VAN DEN BERGHDirector
- JANE TAYLORDirector
- MATT IRELANDDirector
- Offering amount
- $40.3M
- Amount sold
- $38.9M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.4MraisedJul 2020 · 22 investors · PharmaceuticalsRule 506(b)
▶$20.4MraisedJul 2020 · 22 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- LIAM GALLACHERDirector
- ERIC RUSSELLDirector
- GREG ARCHAMBEAUExecutive Officer
- JANE TAYLORDirector
- MATT IRELANDDirector
- BERT VAN DEN BERGHDirector
- JAMES NORDSTROMDirector
- Offering amount
- $26.8M
- Amount sold
- $20.4M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedJun 2018 · 6 investors · PharmaceuticalsRule 506(b)
▶$6MraisedJun 2018 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- MATT IRELANDDirector
- JANE TAYLORDirector
- JEFFREY SMITHDirector
- ERIC RUSSELLDirector
- GREG ARCHAMBEAUExecutive Officer
- JIM NORDSTROMDirector
- Offering amount
- $12M
- Amount sold
- $6M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14MraisedJul 2016 · 11 investors · BiotechnologyRule 506(b)
▶$14MraisedJul 2016 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- MARSHA RUSSELLDirector
- BERT VAN DEN BERGHExecutive Officer
- ERIC RUSSELLDirector
- TROY ALSTEADDirector
- GREG ARCHAMBEAUExecutive Officer
- BRUCE BUSKIRKExecutive Officer
- LEE HUNTSMANDirector
- SCOTT WALCHEKDirector
- PATRICK CARUANADirector
- Offering amount
- $14M
- Amount sold
- $14M
- Minimum investment
- $27.7K
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.5MraisedMay 2014 · 3 investors · BiotechnologyRule 506(b)
▶$13.5MraisedMay 2014 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric RussellExecutive Officer, Director
- Lee HuntsmanDirector
- Marsha RussellDirector
- Scott WalcheckDirector
- Patrick CaruanaDirector
- Karl BandlienDirector
- Offering amount
- $40M
- Amount sold
- $13.5M
- Minimum investment
- $500K
- Proceeds to insiders
- $200K
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Revalia Bio, Inc.7 shared keywordsRevalia Bio uses AI to convert donated human organs and tissues into multi-modal biological datasets and decision-ready insights for drug and device development. It operates an Organ ICU facility and works with organ procurement organizations and healthcare institutions to serve pharma, biotech, and medical device companies.
Vesalio6 shared keywordsVesalio develops thrombectomy devices, including its enVast system used in cardiovascular procedures such as PCI. The company works in the medical device field, running clinical trials to evaluate the safety and effectiveness of its products.
Imperative Care Inc5 shared keywordsImperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey. The company focuses on devices and solutions for patients suffering from devastating vascular conditions.
Renovo Rx4 shared keywordsRenovoRx develops targeted oncology therapies and commercializes the RenovoCath, an FDA-cleared drug-delivery device for intra-arterial chemotherapy administration in cancer treatment. The company is conducting Phase III clinical trials of its proprietary TAMP therapy platform for treating locally advanced pancreatic cancer with improved safety and efficacy compared to systemic chemotherapy.
Vesalius Therapeutics4 shared keywordsVesalius Therapeutics develops a computational platform that identifies distinct disease subtypes within common diseases like heart failure, diabetes, and Alzheimer's by analyzing patient data and gene circuits, then uses proprietary cell-based models to discover targeted drug candidates. The company serves patients with prevalent chronic diseases using artificial intelligence, genomics, and patient-derived experimental models.
IQVIA4 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Companies competing with Revalesio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Revalesio do?
- Revalesio is a clinical-stage pharmaceutical company developing therapies that target mitochondrial function to address the bioenergetic and metabolic failures underlying stroke, neurodegenerative diseases, and aging. It focuses on protecting mitochondrial structure and restoring cellular homeostasis for patients with neurological conditions lacking effective treatment options.
- How much funding has Revalesio raised?
- Revalesio has disclosed $92.7M raised across 5 rounds.
- Where is Revalesio headquartered?
- Revalesio is headquartered in Tacoma, US.